Diagnosis and treatment of giant cell arteritis

Fabrizio Cantini, Laura Niccoli, Carlotta Nannini, Michele Bertoni, Carlo Salvarani

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Giant cell arteritis (GCA) is a chronic granulomatous vasculitis of unknown aetiology occurring in the elderly. It affects the cranial branches of the arteries originating from the aortic arch and is usually associated with markedly elevated acute-phase reactants. In 10-15% of cases the extra-cranial branches of the aortic arch are involved. GCA is closely related to polymyalgia rheumatica (PMR), although the relationship between the two disorders is still unclear. New-onset headache, scalp tenderness, jaw claudication, temporal artery abnormalities on physical examination, visual symptoms and associated PMR represent the most typical and frequent features of the disease. Systemic manifestations, including fever, anorexia and weight loss, are observed in 50% of cases. Less frequent manifestations are related to the central or peripheral nervous systems, the respiratory tract and extra-cranial large-vessel involvement. As GCA is characterized by a wide spectrum of clinical manifestations, it is important to recognize the different onset patterns of the disease and related diagnostic steps. The diagnosis is relatively straightforward in the presence of typical cranial manifestations, but it may be challenging in the case of a normal erythrocyte sedimentation rate, occult GCA or in patients with isolated extra-cranial features. Temporal artery biopsy still represents the gold standard for diagnosis, while the role of ultrasonography, high-resolution magnetic resonance imaging and positron emission tomography should be better addressed. Corticosteroids remain the therapy of choice. Data supporting the usefulness of antiplatelet agents and anticoagulants combined with corticosteroids to prevent ischaemic complications as well as the corticosteroid-sparing effect of methotrexate and anti-tumour necrosis factor-α drugs are limited and non-conclusive.

Original languageEnglish
Pages (from-to)281-297
Number of pages17
JournalDrugs and Aging
Volume25
Issue number4
Publication statusPublished - 2008

Fingerprint

Giant Cell Arteritis
Polymyalgia Rheumatica
Temporal Arteries
Adrenal Cortex Hormones
Thoracic Aorta
Acute-Phase Proteins
Platelet Aggregation Inhibitors
Blood Sedimentation
Peripheral Nervous System
Anorexia
Therapeutics
Vasculitis
Jaw
Scalp
Methotrexate
Respiratory System
Positron-Emission Tomography
Anticoagulants
Physical Examination
Headache

Keywords

  • Corticosteroids, therapeutic use
  • Giant cell arteritis, treatment
  • Infliximab, therapeutic use
  • Methotrexate, therapeutic use
  • Tumour necrosis factor antagonists, therapeutic use

ASJC Scopus subject areas

  • Pharmacology
  • Geriatrics and Gerontology

Cite this

Cantini, F., Niccoli, L., Nannini, C., Bertoni, M., & Salvarani, C. (2008). Diagnosis and treatment of giant cell arteritis. Drugs and Aging, 25(4), 281-297.

Diagnosis and treatment of giant cell arteritis. / Cantini, Fabrizio; Niccoli, Laura; Nannini, Carlotta; Bertoni, Michele; Salvarani, Carlo.

In: Drugs and Aging, Vol. 25, No. 4, 2008, p. 281-297.

Research output: Contribution to journalArticle

Cantini, F, Niccoli, L, Nannini, C, Bertoni, M & Salvarani, C 2008, 'Diagnosis and treatment of giant cell arteritis', Drugs and Aging, vol. 25, no. 4, pp. 281-297.
Cantini F, Niccoli L, Nannini C, Bertoni M, Salvarani C. Diagnosis and treatment of giant cell arteritis. Drugs and Aging. 2008;25(4):281-297.
Cantini, Fabrizio ; Niccoli, Laura ; Nannini, Carlotta ; Bertoni, Michele ; Salvarani, Carlo. / Diagnosis and treatment of giant cell arteritis. In: Drugs and Aging. 2008 ; Vol. 25, No. 4. pp. 281-297.
@article{004f63c211e34796af92a76f0a4322bf,
title = "Diagnosis and treatment of giant cell arteritis",
abstract = "Giant cell arteritis (GCA) is a chronic granulomatous vasculitis of unknown aetiology occurring in the elderly. It affects the cranial branches of the arteries originating from the aortic arch and is usually associated with markedly elevated acute-phase reactants. In 10-15{\%} of cases the extra-cranial branches of the aortic arch are involved. GCA is closely related to polymyalgia rheumatica (PMR), although the relationship between the two disorders is still unclear. New-onset headache, scalp tenderness, jaw claudication, temporal artery abnormalities on physical examination, visual symptoms and associated PMR represent the most typical and frequent features of the disease. Systemic manifestations, including fever, anorexia and weight loss, are observed in 50{\%} of cases. Less frequent manifestations are related to the central or peripheral nervous systems, the respiratory tract and extra-cranial large-vessel involvement. As GCA is characterized by a wide spectrum of clinical manifestations, it is important to recognize the different onset patterns of the disease and related diagnostic steps. The diagnosis is relatively straightforward in the presence of typical cranial manifestations, but it may be challenging in the case of a normal erythrocyte sedimentation rate, occult GCA or in patients with isolated extra-cranial features. Temporal artery biopsy still represents the gold standard for diagnosis, while the role of ultrasonography, high-resolution magnetic resonance imaging and positron emission tomography should be better addressed. Corticosteroids remain the therapy of choice. Data supporting the usefulness of antiplatelet agents and anticoagulants combined with corticosteroids to prevent ischaemic complications as well as the corticosteroid-sparing effect of methotrexate and anti-tumour necrosis factor-α drugs are limited and non-conclusive.",
keywords = "Corticosteroids, therapeutic use, Giant cell arteritis, treatment, Infliximab, therapeutic use, Methotrexate, therapeutic use, Tumour necrosis factor antagonists, therapeutic use",
author = "Fabrizio Cantini and Laura Niccoli and Carlotta Nannini and Michele Bertoni and Carlo Salvarani",
year = "2008",
language = "English",
volume = "25",
pages = "281--297",
journal = "Drugs and Aging",
issn = "1170-229X",
publisher = "Springer International Publishing",
number = "4",

}

TY - JOUR

T1 - Diagnosis and treatment of giant cell arteritis

AU - Cantini, Fabrizio

AU - Niccoli, Laura

AU - Nannini, Carlotta

AU - Bertoni, Michele

AU - Salvarani, Carlo

PY - 2008

Y1 - 2008

N2 - Giant cell arteritis (GCA) is a chronic granulomatous vasculitis of unknown aetiology occurring in the elderly. It affects the cranial branches of the arteries originating from the aortic arch and is usually associated with markedly elevated acute-phase reactants. In 10-15% of cases the extra-cranial branches of the aortic arch are involved. GCA is closely related to polymyalgia rheumatica (PMR), although the relationship between the two disorders is still unclear. New-onset headache, scalp tenderness, jaw claudication, temporal artery abnormalities on physical examination, visual symptoms and associated PMR represent the most typical and frequent features of the disease. Systemic manifestations, including fever, anorexia and weight loss, are observed in 50% of cases. Less frequent manifestations are related to the central or peripheral nervous systems, the respiratory tract and extra-cranial large-vessel involvement. As GCA is characterized by a wide spectrum of clinical manifestations, it is important to recognize the different onset patterns of the disease and related diagnostic steps. The diagnosis is relatively straightforward in the presence of typical cranial manifestations, but it may be challenging in the case of a normal erythrocyte sedimentation rate, occult GCA or in patients with isolated extra-cranial features. Temporal artery biopsy still represents the gold standard for diagnosis, while the role of ultrasonography, high-resolution magnetic resonance imaging and positron emission tomography should be better addressed. Corticosteroids remain the therapy of choice. Data supporting the usefulness of antiplatelet agents and anticoagulants combined with corticosteroids to prevent ischaemic complications as well as the corticosteroid-sparing effect of methotrexate and anti-tumour necrosis factor-α drugs are limited and non-conclusive.

AB - Giant cell arteritis (GCA) is a chronic granulomatous vasculitis of unknown aetiology occurring in the elderly. It affects the cranial branches of the arteries originating from the aortic arch and is usually associated with markedly elevated acute-phase reactants. In 10-15% of cases the extra-cranial branches of the aortic arch are involved. GCA is closely related to polymyalgia rheumatica (PMR), although the relationship between the two disorders is still unclear. New-onset headache, scalp tenderness, jaw claudication, temporal artery abnormalities on physical examination, visual symptoms and associated PMR represent the most typical and frequent features of the disease. Systemic manifestations, including fever, anorexia and weight loss, are observed in 50% of cases. Less frequent manifestations are related to the central or peripheral nervous systems, the respiratory tract and extra-cranial large-vessel involvement. As GCA is characterized by a wide spectrum of clinical manifestations, it is important to recognize the different onset patterns of the disease and related diagnostic steps. The diagnosis is relatively straightforward in the presence of typical cranial manifestations, but it may be challenging in the case of a normal erythrocyte sedimentation rate, occult GCA or in patients with isolated extra-cranial features. Temporal artery biopsy still represents the gold standard for diagnosis, while the role of ultrasonography, high-resolution magnetic resonance imaging and positron emission tomography should be better addressed. Corticosteroids remain the therapy of choice. Data supporting the usefulness of antiplatelet agents and anticoagulants combined with corticosteroids to prevent ischaemic complications as well as the corticosteroid-sparing effect of methotrexate and anti-tumour necrosis factor-α drugs are limited and non-conclusive.

KW - Corticosteroids, therapeutic use

KW - Giant cell arteritis, treatment

KW - Infliximab, therapeutic use

KW - Methotrexate, therapeutic use

KW - Tumour necrosis factor antagonists, therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=41149143541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149143541&partnerID=8YFLogxK

M3 - Article

C2 - 18361539

AN - SCOPUS:41149143541

VL - 25

SP - 281

EP - 297

JO - Drugs and Aging

JF - Drugs and Aging

SN - 1170-229X

IS - 4

ER -